Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mayo Clinic
With
Congressionally Directed Medical Research Programs
PRIMARY OBJECTIVES:
I. To evaluate a highly innovative project evaluating the feasibility of patient-centered home care PCHC as a new model of cancer care to reduce disparities and improve health related QoL (HRQoL) and patient reported-outcomes (PROs) in Black patients with advanced prostate cancer (CaP). (Phase I) II. Establish patient-centeredness by exploring patients' choice relative to the place of CaP treatment for certain aspects of therapy as well as end-of-life care.
III. Establish the acceptance and impact of PCHC on PROs and HRQoL in BM with advanced CaP.
OUTLINE: This is an observational study. Participants are assigned to 1 of 2 groups.
GROUP 1: Participants take part in a focus group or complete questionnaires and may take part in an interview on study.
GROUP 2: Participants complete questionnaires throughout the study.
Age
18–any
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
GROUP 1 FOCUS GROUPS:
* Individuals identifying as Black and male who are familiar with the landscape of medical care and cancer
GROUP 1 SURVEYS:
* Are 18 years of age or older
* Have histologic evidence of prostate adenocarcinoma
* Are requiring, have required, or will require prostate cancer treatment
* Have an understanding of the protocol and its requirements
* Are willing to fill in a questionnaire and participate in a focused interview
* Are able and willing to sign an informed consent
GROUP 1 INTERVIEWS:
* Enrollment in the survey phase of the protocol
GROUP 2:
* Are 18 years of age or older
* Are Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges)
* Have histologic evidence of prostate adenocarcinoma
* Are requiring active standard hormone-based therapies (degarelix or leuprolide), antibone resorptive agents (zoledronic acid or denosumab), oral anticancer treatments (abiraterone or second-generation androgen receptor blockers) or intravenous chemotherapy (docetaxel)
* Are receiving part of supportive care/symptom management and/or anti-cancer therapy in the home as part of Cancer Care Beyond Walls (CCBW)
* Have an understanding of the protocol and its requirements
* Are able and willing to sign informed consent
You may not be if
GROUP 1 FOCUS GROUPS:
* Individuals who do not identify as Black or male or who have had no extensive interaction with the healthcare system
GROUP 1 SURVEYS:
* Do not identify as Black men
* Have not been diagnosed with prostate cancer
GROUP 1 INTERVIEWS:
* Not enrolled in the survey phase of the protocol
GROUP 2:
* Do not identify as Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges)
* Have not been diagnosed with histologic evidence of prostate adenocarcinoma
* Are not requiring active standard anti-cancer therapy
